ReviewOncology letters2018
MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Assessment of extracellular vesicle microRNAs detection in predicting benign and malignant pulmonary ground glass nodules.Frontiers in medicine · 2025Article
- microRNA 21 and long non-coding RNAs interplays underlie cancer pathophysiology: A narrative review.Non-coding RNA research · 2024Review
- Sensitive Multiplexed MicroRNA Spatial Profiling and Data Classification Framework Applied to Murine Breast Tumors.Analytical chemistry · 2024Article
- MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway.Cell death discovery · 2024Article
- Extracellular Vesicles from Cerebrospinal Fluid of Leptomeningeal Metastasis Patients Deliver MiR-21 and Induce Methotrexate Resistance in Lung Cancer Cells.International journal of molecular sciences · 2024Article
- Article
- Review
- The use of biomarkers in the diagnosis of lung cancer.La Tunisie medicale · 2023Article
- Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer.International journal of molecular sciences · 2023Review
- Extracellular Vesicle-microRNAs as Diagnostic Biomarkers in Preterm Neonates.International journal of molecular sciences · 2023Review
- The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.International journal of molecular sciences · 2023Review
- Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19.Seminars in cancer biology · 2022Review
- MicroRNAs as Potential Biomarkers in the Differential Diagnosis of Lipomatous Tumors and Their Mimics.International journal of molecular sciences · 2022Article
- Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring.Journal of oncology · 2022Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- Review
- A simple "signal off-on" fluorescence nanoplatform for the label-free quantification of exosome-derived microRNA-21 in lung cancer plasma.Mikrochimica acta · 2021Article
- MiRNA-21 Regulates Bronchial Epithelial Cell Proliferation by Activating Tgfβ1/Smad Signaling Pathway and Its Correlation with Asthma Severity in Children.Iranian journal of public health · 2021Article
- The Clinical Significance of miR-21 in Guiding Chemotherapy for Patients with Osteosarcoma.Pharmacogenomics and personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer worldwide. The high mortality rate of NSCLC is due to a limited number of diagnosis being made at an early stage of disease. Therefore, the development of a novel biological marker for the diagnosis and prognosis prediction of NSCLC remains urgent. Current literature shows that microRNA-21 (miRNA-21/miR-21), as an oncogenic miRNA, is involved in the growth, metastasis and apoptosis of NSCLC cells through its control of various target molecules and signaling pathways. Notably, a growing body of evidence further shows that miR-21 is closely associated with the prognosis prediction, recurrence and diagnosis of cancer patients, indicating that miR-21 may be a novel promising biomarker for the diagnosis and prognosis prediction of NSCLC. The present review aimed to provide a summary of recent findings on the associated progression toward finding a novel biomarker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.